NCT02576912View on ClinicalTrials.gov

Testing the Interactive Effects of Delta-9-Tetrahydrocannabinol and Pregnenolone

PHASE1CompletedINTERVENTIONAL
Enrollment

38

Participants

Timeline

Start Date

February 28, 2015

Primary Completion Date

June 24, 2019

Study Completion Date

June 24, 2019

Conditions
Healthy
Interventions
DRUG

Active Delta-9-THC

Active Delta-9-THC (0.036 mg/kg) given intravenously.

DRUG

Active Pregnenolone

A dose given sublingually.

DRUG

Placebo

A placebo dose given sublingually.

DRUG

Placebo

Placebo dose given intravenously.

Trial Locations (1)

06516

Biological Studies Unit at the VA Connecticut Healthcare System, Yale School of Medicine, West Haven

All Listed Sponsors
lead

Yale University

OTHER

NCT02576912 - Testing the Interactive Effects of Delta-9-Tetrahydrocannabinol and Pregnenolone | Biotech Hunter | Biotech Hunter